In January, Genmab announced a new pre-clinical product, HuMax-CD32b. The antibody may have therapeutical potential in the treatment of B-cell chronic lymphocytic leukemia, small lymphocytic lymphoma, Burkitt's lymphoma, follicular lymphoma and diffuse large B-cell lymphoma.
We reached the third milestone in the GlaxoSmithKline collaboration in January when the first patient in the Phase III RA program received treatment and we received a payment of DKK 87 million (approx. USD 18 million).
Outlook Genmab is maintaining its financial guidance for the year and continue to project an operating loss of DKK 900 to 1,000 million and a net loss in the range of DKK 800 to 900 million. Revenues for 2008 are expected to be approx. DKK 1.0 billion.
As of December 31, 2007, Genmab had cash, cash equivalents and short-term marketable securities of DKK 3.7 billion. For 2008, we project that our operations together with the DKK 1.2 billion acquisition of the manufacturing facility in Minnesota will lead to a year end cash position of DKK 1.7 to 1.8 billion (approx. USD 360 million to USD 382 million).
Conference Call Genmab will hold a conference call to discuss the first
quarter results tomorrow, Thursday, May 29, 2008, at
3:30 pm CEST
2:30 pm BST
9:30 am EDT
The conference call will be held in English.
The dial in numbers are as follows:
+1-877-857-6173 (in the US) and ask for the Genmab conference call
+1-719-325-4792 (outside the US) and ask for the Genmab conference call
To listen to a live webcast of the call please visit
Relevant slides for the call can be found on http://www.genmab.com prior to the call.
About Genmab A/S Genmab i
|SOURCE Genmab A/S|
Copyright©2008 PR Newswire.
All rights reserved